Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer
- Author
- A Lloyd, D Penson, Sarah Dewilde and L Kleinman
- Organization
- Abstract
- Treatment choices for metastatic prostate cancer are complex and can involve men balancing survival versus quality of life. The present study aims to elicit patient preferences with respect to the attributes of treatments for metastatic prostate cancer through a discrete choice experiment (DCE) questionnaire. Men with recently diagnosed localized prostate cancer were asked to envisage that they had metastatic disease when completing a survey. As expected, men with prostate cancer placed considerable importance on gains in survival; however, avoiding side effects of treatment was also clearly important. Survival gains should be considered alongside side effects when discussing treatment options in metastatic disease.
- Keywords
- hormone treatment, preferences, willingness to pay, ANDROGEN BLOCKADE, FLUTAMIDE, TRIAL
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-8579786
- MLA
- Lloyd, A., et al. “Eliciting Patient Preferences for Hormonal Therapy Options in the Treatment of Metastatic Prostate Cancer.” PROSTATE CANCER AND PROSTATIC DISEASES, vol. 11, no. 2, 2007, pp. 153–59, doi:10.1038/sj.pcan.4500992.
- APA
- Lloyd, A., Penson, D., Dewilde, S., & Kleinman, L. (2007). Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer. PROSTATE CANCER AND PROSTATIC DISEASES, 11(2), 153–159. https://doi.org/10.1038/sj.pcan.4500992
- Chicago author-date
- Lloyd, A, D Penson, Sarah Dewilde, and L Kleinman. 2007. “Eliciting Patient Preferences for Hormonal Therapy Options in the Treatment of Metastatic Prostate Cancer.” PROSTATE CANCER AND PROSTATIC DISEASES 11 (2): 153–59. https://doi.org/10.1038/sj.pcan.4500992.
- Chicago author-date (all authors)
- Lloyd, A, D Penson, Sarah Dewilde, and L Kleinman. 2007. “Eliciting Patient Preferences for Hormonal Therapy Options in the Treatment of Metastatic Prostate Cancer.” PROSTATE CANCER AND PROSTATIC DISEASES 11 (2): 153–159. doi:10.1038/sj.pcan.4500992.
- Vancouver
- 1.Lloyd A, Penson D, Dewilde S, Kleinman L. Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer. PROSTATE CANCER AND PROSTATIC DISEASES. 2007;11(2):153–9.
- IEEE
- [1]A. Lloyd, D. Penson, S. Dewilde, and L. Kleinman, “Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer,” PROSTATE CANCER AND PROSTATIC DISEASES, vol. 11, no. 2, pp. 153–159, 2007.
@article{8579786,
abstract = {{Treatment choices for metastatic prostate cancer are complex and can involve men balancing survival versus quality of life. The present study aims to elicit patient preferences with respect to the attributes of treatments for metastatic prostate cancer through a discrete choice experiment (DCE) questionnaire. Men with recently diagnosed localized prostate cancer were asked to envisage that they had metastatic disease when completing a survey. As expected, men with prostate cancer placed considerable importance on gains in survival; however, avoiding side effects of treatment was also clearly important. Survival gains should be considered alongside side effects when discussing treatment options in metastatic disease.}},
author = {{Lloyd, A and Penson, D and Dewilde, Sarah and Kleinman, L}},
issn = {{1365-7852}},
journal = {{PROSTATE CANCER AND PROSTATIC DISEASES}},
keywords = {{hormone treatment,preferences,willingness to pay,ANDROGEN BLOCKADE,FLUTAMIDE,TRIAL}},
language = {{eng}},
number = {{2}},
pages = {{153--159}},
title = {{Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer}},
url = {{http://doi.org/10.1038/sj.pcan.4500992}},
volume = {{11}},
year = {{2007}},
}
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: